Remote Home Assessment of Patients With Amyotrophic Lateral Sclerosis (RHAALS)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06046599 |
Recruitment Status :
Recruiting
First Posted : September 21, 2023
Last Update Posted : September 21, 2023
|
Tracking Information | |||||||||
---|---|---|---|---|---|---|---|---|---|
First Submitted Date | August 29, 2023 | ||||||||
First Posted Date | September 21, 2023 | ||||||||
Last Update Posted Date | September 21, 2023 | ||||||||
Actual Study Start Date | October 24, 2022 | ||||||||
Estimated Primary Completion Date | February 1, 2024 (Final data collection date for primary outcome measure) | ||||||||
Current Primary Outcome Measures |
EMG activity [ Time Frame: 1 year ] Number of fasciculations from electromyography
|
||||||||
Original Primary Outcome Measures | Same as current | ||||||||
Change History | No Changes Posted | ||||||||
Current Secondary Outcome Measures |
|
||||||||
Original Secondary Outcome Measures | Same as current | ||||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||||
Descriptive Information | |||||||||
Brief Title | Remote Home Assessment of Patients With Amyotrophic Lateral Sclerosis | ||||||||
Official Title | Remote Home Assessment of Patients With Amyotrophic Lateral Sclerosis | ||||||||
Brief Summary | The goal of this observational study is the develop new ways of remotely monitoring the health and symptoms of people living with amyotrophic lateral sclerosis from within their homes. The main questions it aims to answer are:
Where possible, researchers will compare the collected data to other neurodegenerative diseases and healthy controls to understand differences over time. |
||||||||
Detailed Description | Amyotrophic lateral sclerosis (ALS), is a neurodegenerative disease that affects nerve cells causing loss of muscle control. Patients with ALS often die within three years of diagnosis. There is only one available drug for ALS, which offers only a small increase to survival by two to three months. The discovery of new drugs for ALS is difficult due to a lack of objective measures that can be used to track disease progression. Consequently, there is a huge need to discover measures that can reliably track ALS over time, which can then be included in clinical trials to speed up drug discovery. Muscle twitches are a distinctive characteristic present in all patients with ALS. These muscle twitches can be seen at the surface of the skin and can be detected accurately with electromyography (EMGs). We predict that these muscle twitches will provide a sensitive measure of disease progression. Due to large dropout rates caused by travelling to and from the hospital, we have built and validated a compact high-density EMG device that sits on the surface of the skin to facilitate repeated assessments from patients' homes. This small device is a tenth of the cost of current devices and has been demonstrated to safely and effectively record muscle twitches. The EMG will be integrated into a digital remote home monitoring platform called Minder. Minder is an established platform for recording internet-enabled medical devices and sensors from within a patient's home. This study aims to establish a home-based digital measure that can track disease progression in patients with ALS. We will recruit 20 patients with ALS from King's Motor Nerve Clinic. Patients will participate in the study for 12-months and will undergo continuous monitoring through the digital monitoring platform alongside regular EMG recordings. |
||||||||
Study Type | Observational | ||||||||
Study Design | Observational Model: Case-Only Time Perspective: Prospective |
||||||||
Target Follow-Up Duration | Not Provided | ||||||||
Biospecimen | Not Provided | ||||||||
Sampling Method | Non-Probability Sample | ||||||||
Study Population | Patients with a diagnosis of amyotrophic lateral sclerosis recruited through King's College Hospital's Motor Nerve Clinic | ||||||||
Condition | Amyotrophic Lateral Sclerosis | ||||||||
Intervention | Not Provided | ||||||||
Study Groups/Cohorts | Patients living with amyotrophic lateral sclerosis
Individuals with a known diagnosis of amyotrophic lateral sclerosis will be recruited from King's College Hospital's Motor Nerve Clinic. The cohort will contain 20 individuals and their study partners and will be part of the study for one year.
|
||||||||
Publications * | Not Provided | ||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||
Recruitment Information | |||||||||
Recruitment Status | Recruiting | ||||||||
Estimated Enrollment |
20 | ||||||||
Original Estimated Enrollment | Same as current | ||||||||
Estimated Study Completion Date | February 1, 2024 | ||||||||
Estimated Primary Completion Date | February 1, 2024 (Final data collection date for primary outcome measure) | ||||||||
Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
Inclusion criteria:
Exclusion criteria:
|
||||||||
Sex/Gender |
|
||||||||
Ages | 18 Years and older (Adult, Older Adult) | ||||||||
Accepts Healthy Volunteers | No | ||||||||
Contacts |
|
||||||||
Listed Location Countries | United Kingdom | ||||||||
Removed Location Countries | |||||||||
Administrative Information | |||||||||
NCT Number | NCT06046599 | ||||||||
Other Study ID Numbers | 296187 | ||||||||
Has Data Monitoring Committee | No | ||||||||
U.S. FDA-regulated Product |
|
||||||||
IPD Sharing Statement |
|
||||||||
Current Responsible Party | King's College London | ||||||||
Original Responsible Party | Same as current | ||||||||
Current Study Sponsor | King's College London | ||||||||
Original Study Sponsor | Same as current | ||||||||
Collaborators |
|
||||||||
Investigators | Not Provided | ||||||||
PRS Account | King's College London | ||||||||
Verification Date | August 2023 |